IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
Key Highlights
- ➤$1.15 billion cash, cash equivalents and marketable securities; runway guidance into 2030 unchanged
- ➤NDA submitted for darovasertib plus crizotinib in metastatic uveal melanoma
- ➤OptimUM-010 enrollment stopped, yielding estimated cost savings of $100-125 million
- ➤IDE849 showed 17.4-month median overall survival in second-line SCLC
- ➤IDEAYA plans two Phase 3 IDE849 registrational trials by year end
Expert Statements
Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences
“We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma.”
Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences
“We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC.”
Yujiro S. Hata, Chief Executive Officer of IDEAYA Biosciences
“Looking ahead, we are excited to share new preclinical data on our extensive MTAP/CDKN2A franchise in RAS-mutant cancers that provides the scientific rationale in support of the two clinical collaborations we established with Roche and Genentech.”
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update PR Newswire
* Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allele status or line of therapy * Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma * Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) presented at ESMO 2026 demonstrates robust anti-tumor activity and encouraging survival benefit in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC); initial data from IDEAYA-sponsored global Phase 1/2 trial expected by the end of 2026 / early 2027 * IDEAYA R&D Day scheduled for November 16th to highlight preclinical data supporting rational combinations that exploit MTAP/CDKN2A deficiency in KRAS-mutant cancers * $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.